Dr Tracy Cunningham is the Chief Medical Officer at Amryt Pharma, a biopharmaceutical rare and orphan diseases company, which she joined in 2020. She is responsible for regulatory affairs, pharmacovigilance/drug safety, quality, and clinical/preclinical development functions. Filsuvez approval for patients with epidermolysis bullosa in Europe has been the most important achievement of the company in June 2022.

Prior to this, she was in AstraZeneca as Clinical Head, Oncology R&D leading the clinical development of several new medicines, including the successful approval of Koselugo (selumetinib) for the treatment of paediatric patients with NF1 plexiform neurofibromas. She has over 20 years’ experience in the pharmaceutical industry predominantly in clinical development and medical affairs.

A 1988 graduate of the Royal College of Surgeons in Ireland and a Fellow of the Royal College of Physicians in Ireland, she specialised in pharmaceutical medicine. She has worked at a senior level in Ireland, at a European level and for the last 10 years at global level in multinational pharmaceutical companies (including Sanofi, GlaxoSmithKline and Novartis) who invest in their respective pipelines of medicines.

She was appointed by the Minister of Health to the Board of the Health Research Board (HRB), Ireland in 2019. She lectures on the Trinity College, Diploma of Pharmaceutical Medicine course on the topic of clinical research.